Literature DB >> 29278654

Up-to-seven criteria as a useful predictor for tumor downstaging to within Milan criteria and Child-Pugh grade deterioration after initial conventional transarterial chemoembolization.

Yutaka Yasui1, Kaoru Tsuchiya1, Masayuki Kurosaki1, Takaya Takeguchi2, Yuko Takeguchi2, Mao Okada1, Wan Wang1, Yohei Kubota1, Tomoyuki Goto1, Yasuyuki Komiyama1,3, Mayu Higuchi1, Kenta Takaura1, Tsuguru Hayashi1,4, Hitomi Takada1,3, Nobuharu Tamaki1, Hiroyuki Nakanishi1, Jun Itakura1, Yuka Takahashi1, Yasuhiro Asahina5, Nobuyuki Enomoto3, Yoshiro Himeno2, Namiki Izumi1.   

Abstract

AIM: Intermediate-stage hepatocellular carcinoma varies widely in tumor burden and liver function. This study aimed to clarify the importance of subclassification by the up-to-seven criteria in both clinical course and liver function deterioration in such patients.
METHODS: We retrospectively analyzed 224 patients with Child-Pugh grade A who underwent initial transarterial chemoembolization (TACE) for hepatocellular carcinoma. Tumor downstaging to within the Milan criteria within 1 year and liver function worsening as Child-Pugh grade deterioration from A to B were analyzed.
RESULTS: The median survival time was 35.8 months. Forty-five patients had no recurrence within 1 year after initial TACE. Of the 179 patients with at least one recurrence within a year, 44 (25%) achieved tumor downstaging to within the Milan criteria and showed significantly longer survival than non-downstaged ones (P = 0.02). Logistic regression univariate analysis revealed that up-to-seven criteria fulfillment was associated with tumor downstaging to within the Milan criteria (odds ratio 2.6; P = 0.007). The median deterioration time was 26.7 months. Multivariate analysis revealed that beyond the up-to-seven criteria (hazard ratio [HR] 1.9; P = 0.005) was an independent factor associated with Child-Pugh grade deterioration, along with serum albumin (HR 1.54; P = 0.01), serum bilirubin (HR 1.49; P = 0.02), and prothrombin time (HR 1.54; P = 0.04).
CONCLUSIONS: The up-to-seven criteria had prognostic value and could predict non-critical recurrence and maintenance of Child-Pugh grade in patients who underwent initial conventional TACE.
© 2017 The Japan Society of Hepatology.

Entities:  

Keywords:  hepatocellular carcinoma; intermediate-stage; liver function; transarterial chemoembolization; up-to-seven criteria

Year:  2018        PMID: 29278654     DOI: 10.1111/hepr.13048

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  14 in total

1.  A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements.

Authors:  Masatoshi Kudo; Kwang-Hyub Han; Sheng-Long Ye; Jian Zhou; Yi-Hsiang Huang; Shi-Ming Lin; Chung-Kwe Wang; Masafumi Ikeda; Stephen Lam Chan; Su Pin Choo; Shiro Miyayama; Ann Lii Cheng
Journal:  Liver Cancer       Date:  2020-05-13       Impact factor: 11.740

2.  A New Treatment Option for Intermediate-Stage Hepatocellular Carcinoma with High Tumor Burden: Initial Lenvatinib Therapy with Subsequent Selective TACE.

Authors:  Masatoshi Kudo
Journal:  Liver Cancer       Date:  2019-09-18       Impact factor: 11.740

Review 3.  Intrahepatic recurrence of hepatocellular carcinoma after resection: an update.

Authors:  Maria Tampaki; George Vasileios Papatheodoridis; Evangelos Cholongitas
Journal:  Clin J Gastroenterol       Date:  2021-03-27

4.  Analyses of Intermediate-Stage Hepatocellular Carcinoma Patients Receiving Transarterial Chemoembolization prior to Designing Clinical Trials.

Authors:  Keisuke Koroki; Sadahisa Ogasawara; Yoshihiko Ooka; Hiroaki Kanzaki; Kengo Kanayama; Susumu Maruta; Takahiro Maeda; Masayuki Yokoyama; Toru Wakamatsu; Masanori Inoue; Kazufumi Kobayashi; Soichiro Kiyono; Masato Nakamura; Naoya Kanogawa; Tomoko Saito; Takayuki Kondo; Eiichiro Suzuki; Shingo Nakamoto; Shin Yasui; Akinobu Tawada; Tetsuhiro Chiba; Makoto Arai; Tatsuo Kanda; Hitoshi Maruyama; Jun Kato; Satoshi Kuboki; Masayuki Ohtsuka; Masaru Miyazaki; Osamu Yokosuka; Naoya Kato
Journal:  Liver Cancer       Date:  2020-07-22       Impact factor: 11.740

5.  Simple Scoring System for Predicting TACE Unsuitable among Intermediate-Stage Hepatocellular Carcinoma Patients in the Multiple Systemic Treatment Era.

Authors:  Atsushi Hiraoka; Takashi Kumada; Kazuya Kariyama; Hidenori Toyoda; Satoshi Yasuda; Kunihiko Tsuji; Takeshi Hatanaka; Satoru Kakizaki; Atsushi Naganuma; Toru Ishikawa; Toshifumi Tada; Koichi Takaguchi; Ei Itobayashi; Noritomo Shimada; Hiroshi Shibata; Takaaki Tanaka; Akemi Tsutsui; Takuya Nagano; Michitaka Imai; Shinichiro Nakamura; Kazuhiro Nouso
Journal:  Oncology       Date:  2021-11-29       Impact factor: 2.935

Review 6.  Up to seven criteria in selection of systemic therapy for hepatocellular carcinoma.

Authors:  Tarik Silk; Mikhail Silk; Jennifer Wu
Journal:  World J Gastroenterol       Date:  2022-06-21       Impact factor: 5.374

Review 7.  Switching to systemic therapy after locoregional treatment failure: Definition and best timing.

Authors:  Sadahisa Ogasawara; Yoshihiko Ooka; Keisuke Koroki; Susumu Maruta; Hiroaki Kanzaki; Kengo Kanayama; Kazufumi Kobayashi; Soichiro Kiyono; Masato Nakamura; Naoya Kanogawa; Tomoko Saito; Takayuki Kondo; Eiichiro Suzuki; Shingo Nakamoto; Akinobu Tawada; Tetsuhiro Chiba; Makoto Arai; Jun Kato; Naoya Kato
Journal:  Clin Mol Hepatol       Date:  2020-01-15

Review 8.  Lenvatinib for Hepatocellular Carcinoma: A Literature Review.

Authors:  Takeshi Hatanaka; Atsushi Naganuma; Satoru Kakizaki
Journal:  Pharmaceuticals (Basel)       Date:  2021-01-06

Review 9.  Prospect of lenvatinib for unresectable hepatocellular carcinoma in the new era of systemic chemotherapy.

Authors:  Takuya Sho; Kenichi Morikawa; Akinori Kubo; Yoshimasa Tokuchi; Takashi Kitagataya; Ren Yamada; Taku Shigesawa; Mugumi Kimura; Masato Nakai; Goki Suda; Mitsuteru Natsuizaka; Koji Ogawa; Naoya Sakamoto
Journal:  World J Gastrointest Oncol       Date:  2021-12-15

10.  A New Tumor Burden Score and Albumin-Bilirubin Grade-Based Prognostic Model for Hepatocellular Carcinoma.

Authors:  Shu-Yein Ho; Po-Hong Liu; Chia-Yang Hsu; Yi-Hsiang Huang; Jia-I Liao; Chien-Wei Su; Ming-Chih Hou; Teh-Ia Huo
Journal:  Cancers (Basel)       Date:  2022-01-27       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.